drugset
drugset / Trial / NCT07238868

An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy

NCT07238868 ↗

Phase 2 Recruiting 144 enrolled Shanghai Zhimeng Biopharma, Inc.
NaSingle-groupOpen-labelTreatment

Summary

CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.

Timeline

Start
2025-08-14
Primary completion
2029-01
Completion
2029-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CB03-154 Unknown 20 mg Oral

Indications

focal epilepsy